[HIMS]

Hims & Hers projects third-quarter revenue to be between $880 million and $900 million, while also raising its annual forecast for 2026 to between $3.1 billion and $3.3 billion. If the price rises towards the resistance level of $37.7, I will take profits at $37.7. Conversely, if there is a breakdown below the support level of $24.24, I will cut losses at $24.24. The current price of $31.77 is positioned between the support level ($24.24) and the resistance level ($37.70). As the price approaches the resistance level in the future, we anticipate profit-taking selling pressure and will consider a cautious approach to entry. RSI(14) is 48.1, moving averages are in a positive alignment, trading volume is 1.21 times the 20-day average, and the recent 7-day volatility is +17.5%. Entering with expectations of an upward trend due to the strong catalysts of raised Q3 revenue forecasts and an upward revision of the 2026 guidance, the actual results fell significantly short of the predicted return of +3.0%, resulting in a decline of -11.4% and breaching the stop-loss line. At the time of entry, the RSI(14) was 48.1, and the stock had recently risen +17.5% over the past 7 days, raising concerns about short-term overheating, which indeed acted as a burden. It could not withstand the profit-taking pressure in the mid-price range between the support level of $24.24 and the resistance level of $37.70, leading to a downward trend. Even with the fundamental positive factor of an upward guidance, if the stock has entered an overheated phase due to a short-term surge, I will thoroughly apply a conservative entry strategy by waiting until the price is sufficiently pressed down near the support level rather than immediately chasing the buy. The pre-history of this stock shows patterns of +28.6% on 2026-07-29, +14.5% on 2026-07-24, -5.9% on 2026-07-23, and -0.3% on 2026-07-18. While there is no direct similarity to the cases of VEEE (451.7%), LRCX (346.8%), and AMD (333.8%), they are used as references for top performance in the region.

**[Section 1: Entry Rationale]** Based on the news of the FDA advisory committee's recommendation for the approval of peptide BPC-157, it was determined that there could be short-term upward potential, prompting consideration for entry. - **Initial Rationale (News Reaction):** The news "Hims & Hers gains as FDA panel endorses peptide BPC-157" confirmed a positive regulatory event, leading to a review of buying opportunities. - **Candle Flow and Observation Period:** After closing at 33.68 from a peak of 37.7 on July 16, the stock price fluctuated between the 31 and 32 range from July 17 to July 23, showing a sideways trend. On July 23, it attempted to rebound to a high of 35.85; however, on July 24, it opened at 33.44 and dropped to a low of 27.92, closing sharply down at 28.09, indicating significant volatility. - **Impact of Additional Related News:** Around the entry point, news such as "Hims & Hers announces departure of chief accounting officer who helped through its IPO" (July 18) and "Hims & Hers down as FDA advisors snub first peptide" (July 24) confirmed executive departures and advisory committee-related news, suggesting that the outcome was influenced by multiple factors rather than a single news event. **[Section 2: Result Comparison]** An expected return of 8.0% was anticipated upon entry; however, the actual result recorded a loss of -19.7%, concluding with a FAILED rating. - **Discrepancy Between Prediction and Actual:** Based on the initial FDA peptide approval recommendation news, an upward trend was anticipated, but on July 24, the stock plummeted from a high of 34.57 to a low of 27.92, reaching the stop-loss level at 28.09. - **Factors Influencing the Result:** The afternoon news on July 24, "Hims & Hers down as FDA advisors snub first peptide," directly contributed to the decline by offsetting the positive regulatory news. Additionally, internal variables such as the resignation news of the Chief Accounting Officer (CAO) announced on July 18 may have also played a complex role. **[Section 3: Adjustments for Future Trading]** Even if similar regulatory-related event news occurs, it is recognized that subsequent advisory committee results or additional negative reports could lead to increased volatility, prompting adjustments to response criteria. - **Actionable Adjustments:** In future trading related to biotech and pharmaceutical events, it is essential to monitor not only the initial approval recommendation news but also any opposing follow-up news ("snub," etc.) that may arise on the same day or the next, as well as real-time monitoring of any breaches of intraday lows. In particular, the detection of order books and related news around significant drops, such as the one observed on July 24 (low of 27.92), should be prioritized in setting stop-loss criteria. - **Reference Case Comparison:** Past successful cases such as AGIO (2026-07-07 13:38:10, +30.6%, Agios gains FDA priority review), VEEE (2026-07-16 12:01:25, +451.7%, Twin Vee PowerCats stock surges 85% on merger announcement), and LRCX (2026-07-06 13:41:02, +346.8%, Why is Lam Research stock surging today?) maintained their prices without being reversed by additional negative news following the positive announcements. In contrast, the HIMS case experienced rapid fluctuations between positive and negative news, so stricter risk management criteria will be applied if opposing follow-up news emerges immediately after a positive announcement in the future.

There is currently no confirmed news regarding HIMS, making it impossible to assess any potential catalysts. If the price reaches the REPORTING output value, I will take profits, and conversely, if that price breaks down, I will cut losses. In recent days, the price, which had been fluctuating around the $14 to $16 range, suddenly surged to $22.16 today, showing significant volatility. The movement breaking out of the previous trading range and strongly pushing upward has been observed, prompting consideration for entry. 1. VEEE (2026-07-16 12:01:25): Return 451.7%, Twin Vee PowerCats stock surges 85% on merger announcement / 2. LRCX (2026-07-06 13:41:02): Return 346.8%, Why is Lam Research stock surging today? / 3. AMD (2026-07-06 14:01:01): Return 333.8%, Why is Advanced Micro Devices stock surging today?